A review of the clinical efficacy and safety of 5α-reductase inhibitors for the enlarged prostate
- 1 January 2007
- journal article
- review article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 29 (1), 17-25
- https://doi.org/10.1016/j.clinthera.2007.01.018
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Enlarged prostate: A landmark national survey of its prevalence and impact on US men and their partnersProstate Cancer and Prostatic Diseases, 2005
- Efficacy and Safety of Long-Term Treatment with the Dual 5α-Reductase Inhibitor Dutasteride in Men with Symptomatic Benign Prostatic HyperplasiaEuropean Urology, 2004
- 5-Alpha Reductase Inhibition Provides Superior Benefits to Alpha Blockade by Preventing AUR and BPH-Related SurgeryEuropean Urology, 2004
- Sustained Decrease in Incidence of Acute Urinary Retention and Surgery With Finasteride for 6 Years in Men With Benign Prostatic HyperplasiaJournal of Urology, 2004
- Alpha-Blocker Therapy Can Be Withdrawn in the Majority of Men Following Initial Combination Therapy with the Dual 5α-Reductase Inhibitor DutasterideEuropean Urology, 2003
- Improvements in benign prostatic hyperplasia‐specific quality of life with dutasteride, the novel dual 5α‐reductase inhibitorBJU International, 2003
- Drug Treatment of Benign Prostatic Hyperplasia and Hospital Admission for BPH-Related SurgeryEuropean Urology, 2003
- Safety and Tolerability of the Dual 5α-Reductase Inhibitor Dutasteride in the Treatment of Benign Prostatic HyperplasiaEuropean Urology, 2003
- LONGITUDINAL CHANGES IN PEAK URINARY FLOW RATES IN A COMMUNITY BASED COHORTJournal of Urology, 2000
- LONGITUDINAL PROSTATE GROWTH RATES DURING 5 YEARS IN RANDOMLY SELECTED COMMUNITY MEN 40 TO 79 YEARS OLDJournal of Urology, 1999